News
A new study shows that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...
8d
News-Medical.Net on MSNTimepoint at which B cells transform into leukemic cells impacts treatment outcomesNew findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...
16d
News-Medical.Net on MSNScaling B-cell cloning workflows for antibody developmentMathieu Bennet: In B-cell cloning, single-cell isolation occurs at two crucial stages. First, during the initial screening ...
Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...
4h
Stockhead on MSNNew Prescient leadership to drive PTX-100 development in rare blood cancerWith a new leadership team and fast-track designation from the US Food and Drug Administration (FDA), clinical-stage oncology ...
17d
Pharmaceutical Technology on MSNHarbour BioMed partners Otsuka on new T-cell therapyHarbour BioMed has entered a strategic partnership with Otsuka focusing on the development of HBM7020 for treating autoimmune ...
Losing excess weight has “hidden benefits” and helps clear out damaged and ageing cells, scientists have discovered. They ...
LG Energy Solution has branched out from electric vehicle batteries to energy storage systems with its new $1.4 billion ...
In this GEN panel discussion, three experts in cell and gene therapy development will share lessons and strategies learned ...
9d
GlobalData on MSNAbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipelineAbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...
AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results